Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

VRTX Vertex Pharmaceuticals Inc

485,00

14,63 (3,11%)

04 Fev 2025 - Fechado

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/15/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/08/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for David Altshuler

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Vertex Pharmaceuticals (NASDAQ:VRTX)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Vertex Pharmaceuticals.

Vertex Pharmaceuticals (NASDAQ:VRTX)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Vertex Pharmaceuticals.

Notícias Vertex Pharmaceuticals Inc

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Sexta, 31 de Janeiro de 2025 (5 dias atrás) • Business Wire

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Quinta, 30 de Janeiro de 2025 (5 dias atrás) • Business Wire

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
Segunda, 27 de Janeiro de 2025 (1 semana atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 17 de Janeiro de 2025 (3 semanas atrás) • Edgar (US Regulatory)

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Domingo, 12 de Janeiro de 2025 (3 semanas atrás) • Business Wire

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
Sexta, 10 de Janeiro de 2025 (4 semanas atrás) • Business Wire

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Terça, 7 de Janeiro de 2025 (4 semanas atrás) • PR Newswire (US)

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Segunda, 23 de Dezembro de 2024 (1 mês atrás) • Business Wire

Form 8-K - Current report
Sexta, 20 de Dezembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Sexta, 20 de Dezembro de 2024 (2 meses atrás) • Business Wire

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Sexta, 20 de Dezembro de 2024 (2 meses atrás) • Business Wire

Resultados mistos de estudo afetam ações da Vertex Pharmaceuticals
Quinta, 19 de Dezembro de 2024 (2 meses atrás) • ADVFN News

Mais Notícias de Vertex Pharmaceuticals Inc

Cellframe Token

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições